135 related articles for article (PubMed ID: 31114314)
1. Increased expression of TMED2 is an unfavorable prognostic factor in patients with breast cancer.
Lin X; Liu J; Hu SF; Hu X
Cancer Manag Res; 2019; 11():2203-2214. PubMed ID: 31114314
[No Abstract] [Full Text] [Related]
2. Screening of the novel immune-suppressive biomarkers of TMED family and whether knockdown of TMED2/3/4/9 inhibits cell migration and invasion in breast cancer.
Fang Z; Song YX; Wo GQ; Zhou HL; Li L; Yang SY; Chen X; Zhang J; Tang JH
Ann Transl Med; 2022 Dec; 10(23):1280. PubMed ID: 36618780
[TBL] [Abstract][Full Text] [Related]
3. Multi-Omics Analysis Identified TMED2 as a Shared Potential Biomarker in Six Subtypes of Human Cancer.
Sial N; Saeed S; Ahmad M; Hameed Y; Rehman A; Abbas M; Asif R; Ahmed H; Hussain MS; Rehman JU; Atif M; Khan MR
Int J Gen Med; 2021; 14():7025-7042. PubMed ID: 34707394
[TBL] [Abstract][Full Text] [Related]
4. Distinct prognosis of mRNA expression of the five RecQ DNA-helicase family members -
Zhu X; Chen H; Yang Y; Xu C; Zhou J; Zhou J; Chen Y
Cancer Manag Res; 2018; 10():6649-6668. PubMed ID: 30584360
[TBL] [Abstract][Full Text] [Related]
5. TMED2/9/10 Serve as Biomarkers for Poor Prognosis in Head and Neck Squamous Carcinoma.
Gao W; Zhang ZW; Wang HY; Li XD; Peng WT; Guan HY; Liao YX; Liu A
Front Genet; 2022; 13():895281. PubMed ID: 35754792
[No Abstract] [Full Text] [Related]
6. Expression and Importance of TMED2 in Multiple Myeloma Cells.
Ge X; Jiang W; Jiang Y; Lv X; Liu X; Wang X
Cancer Manag Res; 2020; 12():12895-12903. PubMed ID: 33364837
[TBL] [Abstract][Full Text] [Related]
7. TMED2/emp24 is required in both the chorion and the allantois for placental labyrinth layer development.
Hou W; Jerome-Majewska LA
Dev Biol; 2018 Dec; 444(1):20-32. PubMed ID: 30236446
[TBL] [Abstract][Full Text] [Related]
8. Significant prognostic values of differentially expressed-aberrantly methylated hub genes in breast cancer.
Qi L; Zhou B; Chen J; Hu W; Bai R; Ye C; Weng X; Zheng S
J Cancer; 2019; 10(26):6618-6634. PubMed ID: 31777591
[No Abstract] [Full Text] [Related]
9. TMED2 promotes epithelial ovarian cancer growth.
Shi-Peng G; Chun-Lin C; Huan W; Fan-Liang M; Yong-Ning C; Ya-Di Z; Guang-Ping Z; Ye-Ping C
Oncotarget; 2017 Nov; 8(55):94151-94165. PubMed ID: 29212217
[TBL] [Abstract][Full Text] [Related]
10. TMED2/p24β1 is expressed in all gestational stages of human placentas and in choriocarcinoma cell lines.
Zakariyah A; Hou W; Slim R; Jerome-Majewska L
Placenta; 2012 Mar; 33(3):214-9. PubMed ID: 22212250
[TBL] [Abstract][Full Text] [Related]
11. High WDR34 mRNA expression as a potential prognostic biomarker in patients with breast cancer as determined by integrated bioinformatics analysis.
Hu DJ; Shi WJ; Yu M; Zhang L
Oncol Lett; 2019 Sep; 18(3):3177-3187. PubMed ID: 31452794
[TBL] [Abstract][Full Text] [Related]
12.
Martinou EG; Moller-Levet CS; Angelidi AM
Am J Cancer Res; 2022; 12(2):585-600. PubMed ID: 35261789
[TBL] [Abstract][Full Text] [Related]
13. DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer.
Nieto-Jiménez C; Alcaraz-Sanabria A; Páez R; Pérez-Peña J; Corrales-Sánchez V; Pandiella A; Ocaña A
Oncotarget; 2017 Sep; 8(38):62834-62841. PubMed ID: 28968952
[TBL] [Abstract][Full Text] [Related]
14. Non-alcoholic fatty liver disease in mice with heterozygous mutation in TMED2.
Hou W; Gupta S; Beauchamp MC; Yuan L; Jerome-Majewska LA
PLoS One; 2017; 12(8):e0182995. PubMed ID: 28797121
[TBL] [Abstract][Full Text] [Related]
15. Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer.
Peng WX; Huang JG; Yang L; Gong AH; Mo YY
Mol Cancer; 2017 Oct; 16(1):161. PubMed ID: 29041978
[TBL] [Abstract][Full Text] [Related]
16. PBX1 is a valuable prognostic biomarker for patients with breast cancer.
Ao X; Ding W; Ge H; Zhang Y; Ding D; Liu Y
Exp Ther Med; 2020 Jul; 20(1):385-394. PubMed ID: 32565927
[TBL] [Abstract][Full Text] [Related]
17. SIRT7 Is a Prognostic Biomarker Associated With Immune Infiltration in Luminal Breast Cancer.
Huo Q; Li Z; Cheng L; Yang F; Xie N
Front Oncol; 2020; 10():621. PubMed ID: 32528869
[No Abstract] [Full Text] [Related]
18. Comprehensive analysis of peroxiredoxins expression profiles and prognostic values in breast cancer.
Mei J; Hao L; Liu X; Sun G; Xu R; Wang H; Liu C
Biomark Res; 2019; 7():16. PubMed ID: 31402980
[TBL] [Abstract][Full Text] [Related]
19. Analysis the prognostic values of solute carrier (SLC) family 39 genes in gastric cancer.
Ding B; Lou W; Xu L; Li R; Fan W
Am J Transl Res; 2019; 11(1):486-498. PubMed ID: 30788004
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinase-1 expression in breast carcinoma: a marker for unfavorable prognosis.
Wang J; Ye C; Lu D; Chen Y; Jia Y; Ying X; Xiong H; Zhao W; Zhou J; Wang L
Oncotarget; 2017 Oct; 8(53):91379-91390. PubMed ID: 29207651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
